Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China VC Watch: Genome, Diagnostics Ventures Attract New Funding

Executive Summary

Genetron Health is the latest emerging Chinese biotech to attract new capital in the push toward precision medicine in China, while the Lilly Asia Fund is among the investors in cancer diagnosis venture Singlera’s Series A.

You may also be interested in...



M&A Analysis: Grail's Chinese Merger Wraps Up Busy May

It was a robust month for medtech M&A deal making with 17 deals in May, making it the busiest month of the year to date. The total number of acquisitions beat the number recorded in May last year and picked up slightly from the 14 deals inked in the previous month.

China's Ongoing 'COVID Zero' Policies To Prompt More Domestic Deals?

China biotechs appear increasingly interested in partnering with domestic counterparts amid signs the Chinese government's restrictive "COVID Zero" policies are likely to stay until well into 2023.

US-China Decoupling Gets On Biotech's Nerves

The Biden Administration’s latest Executive Order is aimed at shoring up investment in the US and securing supply chains for pharma and biotech products and is already impacting China's CDMO sector, but the long-term impact may be more nuanced, experts predict.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT103867

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel